InsiderClue
← All stocks

MapLight Therapeutics, Inc.

MPLT Net buying
CIK 0001770069 #3078 in the set updated 21 Sep 2026
Bought (12 mo)
$174.93M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$29.18M
$20.04M on a plan · $0.00 straight out of an exercise
Sold at will
$9.14M
51 of 139 sales
Net
+$145.75M
+$165.79M against sales at will

By person

16 insiders · 151 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Catalyst4, Inc. entity
10% owner
$157.89M (6)
—
+$157.89M
25,306,689
59.63%
$295.33M
—
Novo Holdings A/S entity
10% owner
$16.20M (1)
—
+$16.20M
3,686,622
8.69%
$43.02M
—
Kroeger Christopher A.
Chief Executive Officer
—
$12.54M (29) scheduled
−$12.54M
1,269,600
2.99%
$14.82M
−20.7%
GILLIS JONATHAN
CAO and Interim CFO
—
$3.56M (13) scheduled
−$3.56M
152,482
0.3593%
$1.78M
−36.5%
Foff Erin Pennock
Chief Medical Officer
—
$3.38M (22) scheduled
−$3.38M
312,261
0.7358%
$3.64M
−19.3%
Kreitzer Anatol
Chief Discovery Officer
—
$2.78M (11) scheduled
−$2.78M
180,926
0.4263%
$2.11M
−30.4%
Lillie James Woodruff
Chief Scientific Officer
—
$2.56M (20) scheduled
−$2.56M
210,110
0.4951%
$2.45M
−31.0%
Hanson Kristopher
General Counsel
—
$1.66M (19) scheduled
−$1.66M
137,044
0.3229%
$1.60M
−25.2%
Malenka Robert C.
Director
—
$1.60M (14)
−$1.60M
348,138
0.8204%
$4.06M
−11.4%
Setia Vishwas
Chief Financial Officer
—
$1.10M (11) scheduled
−$1.10M
356,256
0.8395%
$4.16M
−5.7%
Pavlov George
Director
$441.17K (3)
—
+$441.17K
28,932
0.0682%
$337.64K
—
Garnett Timothy John
Director
$252.68K (1)
—
+$252.68K
67,581
0.1593%
$788.67K
+56.3%
Cox Troy
Director
$148.70K (1)
—
+$148.70K
23,484
0.0553%
$274.06K
—
Walker Maria C
Director
—
—
—
62,703
0.1478%
$731.74K
+19.5%
Babler Martin
Director
—
—
—
7,864
0.0185%
$91.77K
—
Luneborg Nanna Liebach
Director
—
—
—
3,932
0.0093%
$45.89K
—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 76
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 88
Sales straight out of an exercise 0
Sales at will 51
Transactions with no price 0
Shares from compensation/vesting 18,075,000
History held since 28 Oct 2025